A novel preclinical tool to unlock the potential of IL-18 in cancer immunotherapy: genO-hIL-18/hIL-18R mice

Angela Pappalardo, Gaelle H. Martin, Patricia Isnard-Petit, Julie Gorry, Fabiane Sônego, Kader Thiam
genOway, Lyon, 69007, France

AACR 2026
Abstract #5869

Background: Interleukin-18 (IL-18) has emerged as a promising immunomodulatory cytokine in immuno-oncology due to its ability to enhance both innate and adaptive immune responses. It promotes IFN-γ production by T and NK cells, thereby amplifying anti-tumor immunity, especially when combined with checkpoint inhibitors or engineered pro-drugs to resist natural inhibition by IL-18BP. Recent studies suggest that IL-18-based therapies may overcome resistance mechanism in "cold" tumors, making them responsive to immunotherapies[1]. Humanized mouse models expressing human IL-18R are essential to accurately assess efficacy and guide development of human-directed IL-18-based therapies. Therefore, we describe here a new IL-18/IL-18R double humanized mouse model to assess the efficacy of therapeutics targeting the IL-18/IL-18R axis.

1. Mouse IL-18 partially induces signaling through human IL-18Rα/β, requiring humanization of both IL-18 and IL-18Rα/β to maintain functional IL-18/IL-18R axis



B16F10 cells stably expressing mouse or human IL-18Rα/β were stimulated with recombinant mouse or human IL-18 (10 ng/mL) for 24 hours. Mouse IL-6 secretion in the supernatant was then assessed by ELISA.

2. Humanization of both IL-18 and IL-18R does not alter immune cell distribution



Freshly isolated splenocytes, gated on live $CD3^+$ $CD19^-$ (T cells) and $CD3^-$ $CD19^+$ (B cells), in $CD3^-CD19^-$cells: $NKp46^+$ (NK cells), $CD317^+$ (pDC), $Ly\text{-}6G^+$ (Neutrophils), $Ly\text{-}6G^-$ $CD11c^+$ $MHCII^+$ (cDC) and $Ly\text{-}6G^-$ $Ly\text{-}6C^+$ $CD11b^+$ (Monocytes/macrophages). T cell subsets gated on $CD3^+$ $TCRb^+$ $TCR\gamma\delta^-$: $CD4^-$ $CD8^+$ (CD8), $CD4^+CD25^-$ $FoxP3^-$(convCD4) and $CD4^+CD25^+FoxP3^+$ (Treg). In cDC: $CD8^+$ $CD11b^-$ (cDC1) and $CD8^-$ $CD11b^+$ (cDC2).

⇒ **Similar results of immune profiling in blood and bone marrow – *data not shown***

3. Human IL-18Rα expression on immune cells from genO-hIL-18/hIL-18R mice



Freshly isolated splenocytes, gated on single live $CD3^-CD19^-$ $NKp46^-$ $CD317^-$ $Ly\text{-}6G^-$ $Ly\text{-}6C^+$ $Ly\text{-}6C^+$ $CD11b^+$ (Monocytes/macrophages), $CD3^-CD19^-$ $NKp46^+$ (NK cells), $CD3^+$ $TCR\beta^+$ $TCR\gamma\delta^-$ $CD4^-$ $CD8^+$ (CD8 T cells), $CD3^+$ $TCR\beta^+$ $TCR\gamma\delta^-$ $CD4^+CD25^-$ $FoxP3^-$(convCD4), $CD3^+$ $TCR\beta^+$ $TCR\gamma\delta^-CD4^+CD25^+FoxP3^+$ (Treg).

4. Human IL-18 induces IFN-γ secretion in splenocytes from genO-hIL-18/hIL-18R mice



Two-way ANOVA test, $*p < 0{,}05$; $**p < 0{,}005$ and $***p < 0{,}001$ *vs* CD3/CD28 + IL-2/IL-12

⇒ **Human IL-18R is functional**

5. Th1 differentiation is unaltered in genO-hIL-18/hIL-18R mice



One-way ANOVA test, $***p < 0{,}001$ *vs* mIL-2/IL-12

⇒ **genO-hIL-18/hIL-18 T cells polarize toward Th1 upon CD3/CD28 activation**

⇒ **IL-12 increases Th1 frequency similarly in WT and genO-hIL-18/hIL-18R T cells**

6. *In vivo* LPS-induced IL-18 and IFN-γ release



⇒ **LPS-induced human IL-18 secretion in genO-hIL-18/hIL-18R mice mirrors mouse IL-18 secretion in WT mice**

⇒ **IFN-γ is secreted in a similar kinetic in genO-hIL-18/hIL-18R and WT mice**

⇒ **mIL-18BP expression is increased by LPS similarly in genO-hIL-18/hIL-18R and WT mice *(data not shown)***

7. *Ex vivo* efficacy of IL-18 agonists



⇒ **Splenocytes from genO-hIL-18/hIL-18R mice treated with engineered hIL-18 exhibit enhanced cell proliferation and increased IFN-γ secretion compared to inactive hIL-18**

Conclusion: Altogether, these results support the suitability of the genO-hIL-18/hIL-18R mouse model for assessment of new therapies targeting this axis.

Reference: 1. Kessel C, Rossig C, Abken H. Weal and woe of interleukin-18 in the T cell therapy of cancer. *Journal for ImmunoTherapy of Cancer*. 2025;13:e010545. https://doi.org/10.1136/jitc-2024-010545

www.genOway.com